NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from ...

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity funding ...

Company to Conduct Conference Call at 2 p.m. Pacific TimeCORONA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) announced today that results for its third quarter ended September 30, 2025 will be reported on Thursday, November 6, 2025 after the close of the market. The company also said that Chief Executive Officer, Hilton Schlosberg, will host an investor conference call that same day at 2 p.m. Pacific Time to review the company’s financial results and operations. The ...

Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growthMELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and corporate initiatives and outlining key ...

NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an investigational antisense oligonucleotide (ASO) for Angelman syndrome (AS). Data from the Aurora study will expand the population of Angelman patients treated to include both younger and older patients and those with other non-deletion AS genotypes not included in ...

VANCOUVER, Canada, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the Company has made the final concession payment on its flagship Cerro Caliche gold project in Sonora, Mexico. In March 2018, the Company, through its wholly owned Mexican subsidiary, Minera Mar de Plata (“MMP”), executed an Option to Purchase and Promise to Assignment Agreement with a resident of Arizona, USA (the “Vendor”) to acquire a 100% inter ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentatio ...

OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (Nasdaq: SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects to achieve record revenue of $83.3 million and record operating income of $3.5 million in Q4 2025. Eric Nielsen, SunPower’s EVP of Sales said, “I am happy to report the integration of Sunder’s salesforce into SunPower has been seamles ...

Core Viewpoint - First Mid Bancshares, Inc. is set to merge with Two Rivers Financial Group, Inc. in a 100% stock transaction, enhancing First Mid's market presence in Iowa [1][3]. Company Overview - Two Rivers Financial Group, Inc. operates 14 branches in central and southeastern Iowa, with total assets of approximately $1.1 billion, $901 million in loans, and $988 million in deposits as of September 30, 2025 [2]. - First Mid Bancshares, Inc. is a community-focused organization with $7.8 billion in assets, providing a range of financial services across multiple states [11]. Transaction Details - Under the merger agreement, Two Rivers shareholders will receive 1.225 shares of First Mid common stock for each share of Two Rivers common stock, valuing the transaction at approximately $94.1 million based on First Mid's share price of $36.80 [3]. - The transaction is expected to be 12.3% accretive to First Mid's earnings per share by 2027, with tangible book value dilution expected to be recovered in 2.1 years [4]. Strategic Rationale - The merger is aimed at expanding First Mid's geographic footprint and enhancing its commitment to community banking [5][6]. - First Mid anticipates achieving cost savings of approximately 27% of Two Rivers' noninterest expenses, with potential revenue synergies not yet included in the estimates [4]. Leadership and Governance - The transaction has received unanimous approval from both companies' boards and is expected to close in the first quarter of 2026, pending regulatory and shareholder approvals [8]. - Shane Zimmerman, CEO of Two Rivers Bank & Trust, will join First Mid as an Executive Vice President and Divisional President post-merger [7]. Advisory and Legal Support - D.A. Davidson & Co. served as the exclusive financial advisor to Two Rivers, while Keefe, Bruyette & Woods, Inc. acted as the financial advisor for First Mid [9].

Core Insights - Clearmind Medicine Inc. is advancing its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the last patient in the first cohort having received treatment [1][5] - The global alcohol-dependency treatment market is projected to grow from approximately $13.2 billion in 2024 to about $20 billion by 2032, indicating a significant unmet need for effective treatments [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to expand its intellectual property [7] Clinical Trial Details - The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - The trial includes six patients treated at prestigious institutions like Johns Hopkins University and Yale School of Medicine, with additional sites activated in Israel [2][3] Market Opportunity - The urgent need for more effective AUD treatments is highlighted by the projected growth of the treatment market, emphasizing the commercial potential for new therapeutic approaches [4]